Camargo Pharmaceutical Services, LLC has received a significant investment from a private investor that will allow Camargo to take a long-term approach to expand and develop new capabilities, drive growth in the 505(b)(2) market, and increase its global presence in drug development consulting.
 
With this investment, Camargo is well positioned to meet our increasing client demand,” says Ken Phelps, chief executive officer of Camargo Pharmaceutical Services. “We are gratified that our partner has shown confidence in the market, our strategy, and capabilities. We look forward to the many opportunities ahead of us.”

Camargo works with every therapeutic division of the U.S. FDA to help provide clients with strategies to navigate the regulatory pathway.